<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="864">
  <stage>Registered</stage>
  <submitdate>31/10/2005</submitdate>
  <approvaldate>8/11/2005</approvaldate>
  <actrnumber>ACTRN12605000719639</actrnumber>
  <trial_identification>
    <studytitle>A comparison of high flow nasal oxygen to high flow face mask oxygen in recently extubated patients.</studytitle>
    <scientifictitle>A randomised crossover trial comparing the efficacy of the Fisher &amp; Paykel Healthcare High Flow Nasal Interface (HFNO) to Hudson Face Mask (FMO) in maintaining PaO2 saturations in recently extubated patients requiring supplemental oxygen to treat hypoxia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Clinical Study number 2005-16</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypoxia</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>During a 30 minute washout period post-extubation, patients will be titrated to receive a fraction of oxygen (FiO2) at a flow rate of 30 lpm. At the end of this period an arterial blood gas sample will be taken. Patients will then be randomised to receive either FMO or HFNO. The FiO2 and flow rate will remain the same. At the end of 30 minutes an ABG will be taken. Patients will then crossover to receive the other mode for 30 minutes with an ABG taken at the end of the period. 
The FMO group will have oxygen supplied via a Hudson Face Mask and a Fisher &amp; Paykel Healthcare MR850 humidifier. The HFNO group will have oxygen supplied via a Fisher &amp; Paykel Healthcare MR880 humidification system.</interventions>
    <comparator>Standard oxygen therapy with Hudson face mask. A Hudson face mask is a simple oxygen mask. (The high flow nasal interface in a wide bore nasal cannula)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Arterial blood gas</outcome>
      <timepoint>Samples will be taken at 30 minutes after each time treatment has been given.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Endpoints include heart rate, blood pressure, respiratory rate, ability to tolerate mode (nurse assessed).</outcome>
      <timepoint>Secondary endpoints will be measured at the same time points as ABG sampling is performed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient reported comfort will be obtained once the patient is able to talk clearly.</outcome>
      <timepoint>When patients are able to talk clearly</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients meeting extubation criteria whose families provide consent and later give delayed consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who do not consent; patients with DNR order.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelope</concealment>
    <sequence>Computer generation with blocking also used</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>11/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fisher and Paykel Healthcare</primarysponsorname>
    <primarysponsoraddress>15 Maurice Paykel Place. East Tamaki. Auckland 2013</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fisher and Paykel Healthcare</fundingname>
      <fundingaddress>15 Maurice Paykel Place. East Tamaki. Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peninsula Health,</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Intensive Care Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Nina Fowler</name>
      <address>Intensive Care Unit
Frankston Hospital
PO Box 52
Frankston VIC 3199</address>
      <phone>+61 3 97848567</phone>
      <fax />
      <email>NFowler@phcn.vic.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Gerard</name>
      <address>15 Maurice Paykel Place
East Tamaki Auckland</address>
      <phone>+64 9 5740100</phone>
      <fax />
      <email>catherine.gerard@fphcare.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>